For research use only. Not for therapeutic Use.
Pipobroman(CAT: I004031) is an antineoplastic agent used in the treatment of chronic myeloid leukemia (CML). It belongs to the class of alkylating agents and works by interfering with the growth of cancer cells. Pipobroman is primarily used in combination with other chemotherapy drugs to manage CML and has shown effectiveness in controlling the progression of the disease.
| Catalog Number | I004031 |
| CAS Number | 54-91-1 |
| Molecular Formula | C10H16Br2N2O2 |
| Purity | ≥95% |
| Target | DNA Alkylator/Crosslinker |
| Solubility | DMSO: ≥ 36 mg/mL |
| Storage | -20°C |
| Reference | </br>1:Association of Vemurafenib and Pipobroman Enhances BRAF-CRAF Dimerization in Squamous Cell Carcinoma. Cassius C, Pages C, Roux J, Lhote R, Lavocat R, Réa D, Bagot M, Mourah S, Battistella M, Lebbé C, Dumaz N.J Invest Dermatol. 2016 Jun;136(6):1302-5. doi: 10.1016/j.jid.2015.12.047. Epub 2016 Feb 15. No abstract available. PMID: 26854489 </br>2:Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD.J Clin Oncol. 2011 Oct 10;29(29):3907-13. doi: 10.1200/JCO.2011.36.0792. Epub 2011 Sep 12. PMID: 21911721 </br>3:Pipobroman gets regulatory approval outside Germany. Tsamaloukas AG.Dtsch Arztebl Int. 2008 Jan;105(4):71-2; author reply 72. doi: 10.3238/arztebl.2008.0071d. Epub 2008 Jan 25. No abstract available. PMID: 19633773 Free PMC Article</br>4:[Multiples squamous cell carcinomas during treatment with pipobroman]. Tchen T, Durlach A, Bernard P, Grange F.Ann Dermatol Venereol. 2007 Jun-Jul;134(6-7):570-1. French. No abstract available. PMID: 17657187 </br>5:Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Kiladjian JJ, Rain JD, Bernard JF, Briere J, Chomienne C, Fenaux P.Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):417-21. Review. PMID: 16810617 </br>6:Cytogenetic response to pipobroman in Philadelphia-positive chronic myeloid leukemia with thrombocythemic onset. Orlandi E, Bernasconi P, Boni M, Calatroni S, Lazzarino M.Ann Hematol. 2005 Feb;84(2):127-8. Epub 2004 Sep 15. No abstract available. PMID: 15378276 </br>7:Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. Passamonti F, Rumi E, Malabarba L, Arcaini L, Orlandi E, Brusamolino E, Pascutto C, Cazzola M, Lazzarino M.Ann Hematol. 2004 Aug;83(8):495-7. Epub 2004 Jun 3. No abstract available. PMID: 15175894 </br>8:Long-term evaluation of 164 patients with essential thrombocythaemia treated with pipobroman: occurrence of leukaemic evolution. De Sanctis V, Mazzucconi MG, Spadea A, Alfò M, Mancini M, Bizzoni L, Peraino M, Mandelli F.Br J Haematol. 2003 Nov;123(3):517-21. PMID: 14617017 </br>9:Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman. Passamonti F, Lazzarino M.Leuk Lymphoma. 2003 Sep;44(9):1483-8. Review. PMID: 14565648 </br>10:Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy. Kiladjian JJ, Gardin C, Renoux M, Bruno F, Bernard JF.Hematol J. 2003;4(3):198-207. PMID: 12764352 |
